Education
About Us
Working with TipRanks
Follow Us
Sartorius Stedim Biotech (GB:0RG8)
LSE:0RG8
Total Valuation
Sartorius Stedim Biotech has a market cap or net worth of €17.49B. The enterprise value is €19.81B.
Market Cap€17.49B
Enterprise Value€19.81B
Share Statistics
Sartorius Stedim Biotech has 97,330,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,330,410
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Sartorius Stedim Biotech’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.44%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)5.44%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee297.91K
Profits Per Employee26.66K
Employee Count9,961
Asset Turnover0.37
Inventory Turnover2.35
Valuation Ratios
The current PE Ratio of Sartorius Stedim Biotech is 67.2. Sartorius Stedim Biotech’s PEG ratio is 1.51.
PE Ratio67.2
PS Ratio6.89
PB Ratio5.00
Price to Fair Value5.00
Price to FCF140.53
Price to Operating Cash Flow31.92
PEG Ratio1.51
Income Statement
In the last 12 months, Sartorius Stedim Biotech had revenue of 2.97B and earned 265.60M in profits. Earnings per share was 2.73.
Revenue2.97B
Gross Profit1.35B
Operating Income549.00M
Pretax Income373.20M
Net Income265.60M
EBITDA867.10M
Earnings Per Share (EPS)2.73
Cash Flow
In the last 12 months, operating cash flow was 547.70M and capital expenditures -393.20M, giving a free cash flow of 154.50M billion.
Operating Cash Flow547.70M
Free Cash Flow154.50M
Free Cash Flow per Share1.59
Dividends & Yields
Sartorius Stedim Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-7.94%
50-Day Moving Average196.49
200-Day Moving Average192.53
Relative Strength Index (RSI)48.55
Average Volume (3m)57.59K
Important Dates
Sartorius Stedim Biotech upcoming earnings date is Apr 23, 2026, Before Open (Confirmed).
Last Earnings DateFeb 3, 2026
Next Earnings DateApr 23, 2026
Ex-Dividend Date―
Financial Position
Sartorius Stedim Biotech as a current ratio of 1.02, with Debt / Equity ratio of 67.24%
Current Ratio1.02
Quick Ratio0.53
Debt to Market Cap0.13
Net Debt to EBITDA2.68
Interest Coverage Ratio3.60
Taxes
In the past 12 months, Sartorius Stedim Biotech has paid 107.30M in taxes.
Income Tax107.30M
Effective Tax Rate0.29
Enterprise Valuation
Sartorius Stedim Biotech EV to EBITDA ratio is 26.25, with an EV/FCF ratio of 156.51.
EV to Sales7.67
EV to EBITDA26.25
EV to Free Cash Flow156.51
EV to Operating Cash Flow42.25
Balance Sheet
Sartorius Stedim Biotech has €426.10M in cash and marketable securities with €2.75B in debt, giving a net cash position of -€2.32B billion.
Cash & Marketable Securities€426.10M
Total Debt€2.75B
Net Cash-€2.32B
Net Cash Per Share-€23.88
Tangible Book Value Per Share-€3.03
Margins
Gross margin is 45.33%, with operating margin of 18.50%, and net profit margin of 8.95%.
Gross Margin45.33%
Operating Margin18.50%
Pretax Margin12.58%
Net Profit Margin8.95%
EBITDA Margin29.22%
EBIT Margin18.50%
Analyst Forecast
The average price target for Sartorius Stedim Biotech is €235.86, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€235.86
Price Target Upside31.94% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―